CardioExchange Archive

CardioExchange, an NEJM practice community for medical professionals dedicated to improving cardiac patient care, was active from 2009 to 2015. CardioExchange fostered discussion between clinicians from across the globe.

November 16th, 2009

At the AHA: Ticagrelor in STEMI

During the Sunday afternoon Late-Breaking Clinical Trials session, the PLATO investigators presented results from a sub-analysis of the 8,430 patients who presented with STEMI in the main trial.  They reported that the reversible oral P2Y12-receptor antagonist, ticagrelor, was associated with reduction in the composite endpoint of MI, stroke, or vascular death when compared to clopidogrel over 1 year.  There was no significant difference in bleeding outcomes.

Categories: General


You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Comments are closed.